ReviewHNO2015
[The epigenome. Target for innovative therapies in head and neck carcinoma].
Review in HNO, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe pathogenesis of head and neck squamous carcinoma (HNSCC) is a complex and multistage process, which is characterized by the accumulation of genetic and epigenetic aberrations. Most of our knowledge concerning the regulation of gene expression by the epigenome is based on changes in DNA methylation and post-translational histone modifications that affect the phenotypic plasticity of cells under physiological and pathological conditions. STATE OF THE ART: Numerous experimental studies have unraveled the impact of epigenetic alterations during initiation and malignant progression of HNSCC and substantiate their contribution in the context of tumor stem cells and treatment resistance. Due to their stability epigenetic modifications serve as promising diagnostic and prognostic biomarkers, and the reversible nature makes key regulators attractive targets for innovative treatment options.
Indexed as
Identifiers
26489412What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.